[Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)
date : 2/22/2022
Tags: AMR
![[Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case05_ENG-top.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
In this study, the usefulness of TDM (Therapeutic Drug Monitoring) for antimicrobial stewardship is reported.
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Announcement] HGPI Declares the Ministry of the Environment-led ‘Deco-Katsu Declaration’ and Participation in the ‘Deco-Katsu’ Supporters (October 16, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-11-27
[Registration Open] (Webinar) HGPI Cooperation with Lancet Countdown 2023 Japan Presentation “Climate Change as a Children’s Health Issue: The Latest Lancet Report Sounds the Alarm for Health Commitments” (December 14, 2023)
-
2023-11-28
[Event Report] The 1st Advisory Board Meeting for Patient and Public Involvement (PPI) Support Project “Necessary Steps for Promoting PPI in Policy Making” (October 3, 2023)
-
2023-11-29
[Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
-
2023-11-30
[Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)